An MRI instead of a surgical procedure helped speed up the wait between diagnosis and treatment, UK research has found ...

Biotech giant Gilead Sciences, Inc. GILD has put up a strong performance amid a volatile market. Shares of this biotech giant ...

First-line pembrolizumab “has consistent antitumor activity and safety” in patients with advanced urothelial carcinoma who are potentially ineligible for platinum‐based chemotherapy, researchers found ...

Ami Fadia, an analyst from Needham, maintained the Buy rating on Bicycle Therapeutics (BCYC – Research Report). The associated price target ...

Our study provides insight into the treatment landscape and outcomes for metastatic urothelial carcinoma in Mexico and highlights the need for improved access to novel therapies. These findings can ...

Adaptimmune Therapeutics plc (NASDAQ:ADAP – Get Free Report) saw a large growth in short interest in December. As of December 31st, there was short interest totalling 5,500,000 shares, a growth of 8.7 ...

ALX Oncology Holdings Inc. (NASDAQ:ALXO – Get Free Report) has earned a consensus recommendation of “Moderate Buy” from the six analysts that are presently covering the firm, Marketbeat.com reports.

Patients with a common aggressive type of bladder cancer could get correct treatment significantly quicker as new research ...

BladderPath trial found that patients with suspected invasive bladder cancer undergoing initial mpMRI were treated faster ...

(RTTNews) - Bicycle Therapeutics plc (BCYC), Monday announced updated topline Phase 1 combination data for zelenectide pevedotin plus pembrolizumab in previously untreated (first-line) ...

The cancer therapeutics market is set to exceed $400 billion. Read why five pharmaceutical companies offer attractive ...